Up-regulation of type 1 plasminogen activator inhibitor messenger RNA with thrombotic changes in renal grafts

Transplantation
Y WangS H Sacks

Abstract

Small vessel thrombosis is a prominent feature in kidneys undergoing vascular rejection. Type I and type 2 plasminogen activator inhibitors (PAI-1 and PAI-2, respectively) are known to mediate thrombosis. To examine the potential role of PAI-1 and PAI-2 in the mediation of vascular injury, the relationship and the time course of gene expression of PAI-1 and PAI-2 with the thrombotic changes in renal grafts were investigated in an unmodified rejection model in rats. Orthotopic renal transplantation was performed from Lewis to dark agouti (DA) rats and from DA to DA isografts; untreated normal rat kidneys were used as controls. The rats were killed on days 1-9 posttransplantation (n=18 in each allograft and isograft group). The grafts were analyzed by histopathology, in situ mRNA hybridization and Northern blot methods. The results show that PAM mRNA was first detected at day 4, when the thrombotic changes in the grafts were first seen, and that this relationship persisted during the time course observed to day 9. There was no detectable PAI-1 mRNA in the control groups and no PAI-2 in either group. In situ hybridization showed that PAI-1 positive cells were predominantly located in the cortical interstitium, consistent with the ...Continue Reading

References

Jan 1, 1990·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·J M Bergstein
Jan 1, 1988·Methods in Enzymology·I Kushner
Jan 1, 1989·Seminars in Thrombosis and Hemostasis·W P FaulkN U Bang
Jan 1, 1988·Enzyme·E K Kruithof
Aug 1, 1968·The Australian and New Zealand Journal of Surgery·J FabreP J Morris

❮ Previous
Next ❯

Citations

May 22, 1998·Transplantation Proceedings·H SchorlemmerR Kurrle
Dec 5, 2009·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·F FavreauT Hauet
May 1, 1997·Expert Opinion on Investigational Drugs·P Charlton
Feb 3, 2006·Journal of the American Society of Nephrology : JASN·Paola PontrelliGiuseppe Grandaliano
May 23, 2000·Journal of the American Society of Nephrology : JASN·Giuseppe GrandalianoMichele Ursi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.